Gemini Therapeutics Company
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Technology:
Rare Genetic Disorders
Industry:
Gene therapy
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
1/1/2015
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
3
Total Funding:
139500001
Estimated Revenue:
Less than $1M
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership